fosdagrocorat
Small moleculeexperimental
Fosdagrocorat is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. The drug reached phase II clinical trials prior to the discontinuation of its development. — Wikipedia
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00812825)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorMODULATOR
NR3C1 modulator
pro-drug of PF-00251802. Indication: Rheumatoid Arthritis
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1- Mol. weight
- 574.54 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaFosdagrocorat ↗
- ChEMBLCHEMBL3137316 ↗
Also known as
- fosdagrocorat
- fosdagrocorat
- fosdagrocorat
- fosdagrocorat
- pf-04171327
- pf-04171327
- pf-04171327
- pf-04171327
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01393639 | Phase 2 | Sep 1, 2011 | Pfizer |
| NCT01362673 | Phase 1 | May 1, 2011 | Pfizer |
| NCT01199900 | Phase 1 | Aug 1, 2010 | Pfizer |
| NCT00938587 | Phase 2 | Oct 1, 2009 | Pfizer |
| NCT00987038 | Phase 1 | Sep 1, 2009 | Pfizer |
| NCT00812825 | Phase 1 | Jan 1, 2009 | Pfizer |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 6 | 2 | 2009 |
1 organizations
Page 1 / 1